Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead
Second Cancer Candidate In Pipeline
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO J Robert Coleman tells Scrip.
